ReviewMolecules (Basel, Switzerland)2026
Microbial Inulinases: Characterization, Properties, and Potential Contribution to Metabolic and Nutritional Health.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Microbial inulinases are enzymes produced by bacteria, yeasts, and fungi that can hydrolyze inulin into fructose and fructooligosaccharides (FOSs). The article discusses the various types of inulinases (exo- and endo-inulinases), microbial sources, biochemical properties, and optimal activity conditions, which are critical for their use in biotechnological and food processes. Special emphasis is placed on inulin degradation products, particularly FOSs, which are known for their prebiotic properties. They promote the growth of beneficial intestinal microbiota, helping to maintain digestive health and improve nutrient absorption. Compounds produced by inulinases may play an important role in the prevention of metabolic diseases such as obesity, type 2 diabetes mellitus, and dyslipidemias by modulating the microbiota and regulating energy metabolism. In conclusion, microbial inulinases are a promising biotechnological tool for developing nutritional strategies to prevent metabolic diseases and improve overall health. Recent evidence demonstrates that advances in recombinant expression systems, enzyme engineering, immobilization technologies, and microbiome research have substantially expanded the industrial and biomedical potential of microbial inulinases. This review highlights emerging trends toward sustainable enzyme production, precision nutrition, and microbiome-targeted functional foods while identifying current limitations and future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.